<DOC>
	<DOCNO>NCT02466347</DOCNO>
	<brief_summary>The objective pivotal study evaluate relative bioavailability Synflutide HFA 250/25 Inhaler SeretideTM 250 EvohalerTM healthy volunteer without charcoal block .</brief_summary>
	<brief_title>Bioequivalence Study Synflutide HFA Inhaler Seretide Evohaler Healthy Volunteers Without Charcoal Block</brief_title>
	<detailed_description>A pivotal , single-dose , randomize , open-label , two-period , two-sequence , two-treatment , crossover , comparative bioavailability study test drug Synflutide HFA 250/25 Inhaler reference drug SeretideTM 250 EvohalerTM healthy volunteer without charcoal block . Fifty healthy , male female volunteer , 20-65 year age , body mass index ( BMI ) within 18.0-30.0 kg/m2 , inclusive , enrol . A single dose 4 puff ( eq . fluticasone propionate 1000μg+salmeterol 100μg valve ) study period . Plasma sample assay fluticasone propionate salmeterol use validated analytical method accord principle Good Laboratory Practice .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>Healthy male female volunteer , age 2065 , inclusive . BMI within 18.030.0 kg/m² , inclusive . Healthy Non Clinical Significant , accord medical history , ECG , Chest Xray physical examination determine Principal Investigator/SubInvestigator . Systolic blood pressure 90139 mmHg , inclusive , diastolic blood pressure 5090 mmHg , inclusive , pulse rate 50100 bpm , inclusive temperature 35.037.4℃ . Clinical laboratory value within PPC 's acceptable range accord PPC SOP VI006 . Ability comprehend inform nature study , assess PPC staff . Capable give write informed consent prior receive study medication . Must able communicate effectively clinic staff . Ability fast least 14 hour consume standard meal . Availability volunteer entire study duration willing adhere protocol requirement . Agree tattoo body pierce end study . Female subject must fulfill least one following : Be surgically sterile minimum 6 month ; Postmenopausal minimum 1 year ; Agree avoid pregnancy use medically acceptable method contraception least 30 day prior study 30 day study end ( last study procedure ) . Known history presence clinically significant hepatic ( e.g . active liver disease , hepatic impairment ) , renal/genitourinary ( e.g . renal impairment ) , gastrointestinal , cardiovascular , cerebrovascular , pulmonary , endocrine ( e.g . hypothyroidism ) , immunological , musculoskeletal ( e.g . myopathy , rhabdomyolysis ) , neurological , psychiatric , dermatological hematological disease condition unless determine clinically significant Principal Investigator/SubInvestigator . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , condition know interfere absorption , distribution , metabolism excretion drug experience within 7 day prior first drug administration , determine Principal Investigator/SubInvestigator . Presence clinically significant illness within 30 day prior first dosing , determine Principal Investigator/SubInvestigator . Presence significant physical organ abnormality determine Principal Investigator/SubInvestigator . A positive test result follow : HIV , Hepatitis B surface antigen , Hepatitis C , drug abuse ( amphetamine , barbiturate , benzodiazepine , cocaine , opiates , phencyclidine , tetrahydrocannabinol ) , breath alcohol test . Positive pregnancy test female subject . Known history presence : Alcohol abuse dependence within one year prior first drug administration ; Drug abuse dependence ; Hypersensitivity idiosyncratic reaction fluticasone propionate , salmeterol xinafoate , excipients , and/or related substance ; Food allergy and/or presence dietary restriction ; Severe allergic reaction ( e.g . anaphylactic reaction , angioedema ) . Intolerance and/or difficulty blood sample venipuncture . Abnormal diet pattern ( reason ) four week precede study , include fasting , high protein diet etc . Individuals donate , day prior first drug administration : Less 250 mL blood previous 60 day 300 mL previous 90 day Donation plasma plasmapheresis within 7 day prior first drug administration . Individuals participate another clinical trial receive investigational drug within 30 day prior first drug administration . Consumption food beverage contain caffeine/methylxanthines , poppy seed and/or alcohol within 48 hour dose contain grapefruit and/or pomelo within 10 day prior first drug administration . Use prescription medication investigational medication within 30 day prior first drug administration . Use overthecounter medication ( include oral multivitamin , herbal and/or dietary supplement ) within 30 day prior first drug administration ( except spermicidal/barrier contraceptive product ) . Females take oral transdermal hormonal contraceptive within 30 day prior first drug administration . Females use implant , inject , intravaginal , intrauterine hormonal contraceptive within 6 month prior first drug administration . Individuals undergone major surgery within 6 month prior start study , unless deem otherwise Principal Investigator/SubInvestigator . Known history smoke use tobacco product , nicotine product ( patch , gum etc . ) within 6 month prior first drug administration . Pregnant/lactating woman . Subjects give train ensure subject able correctly use investigational product screen . The subject unable operate investigational product proficiently include study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>